ShEEP Request for a SpectraMax M Series Multi-Mode Microplate Reader

点击翻译按钮获取中文摘要

In this application, we request funds from the ORD Shared Equipment Evaluation Program (ShEEP) to purchase a Multi-Mode Microplate Reader. This instrument will be a shared resource to be housed in the Research Service of the Omaha VA Medical Center. Specifically, we seek to obtain a Spectra Max M Series Multi-Mode Microplate Reader. The SpectraMax M series allows for both cuvette and microplate reading and detection by UV, visible, fluorescence and luminescence. This important piece of equipment will provide state-of-the art capabilities not currently available on our VAMC campus. It will replace our current microplate reader, which is 10 years old and needs extensive and expensive repairs. With this new instrument, there is no need to utilize expensive filters to optimize detection levels and background. The optical systems use two scanning monochromators, so that the user can determine optimal excitation and emission settings, resulting in assay performance similar to that of dedicated single-mode readers. Additionally, the Spectra Max M Series offers the capability of measuring the depth (optical pathlength) of samples with no temperature dependency, using the patented PathCheck® Sensor technology. With SoftMax Pro Software, the PathCheck Sensor automatically normalizes the well absorbance. This eliminates the need for standard curves, and for compounds with known absorbance properties, enabling users to calculate concentrations directly from absorbance. The microplate reader will be extensively used by our investigators in the Research Service of the Omaha VAMC. The instrument will enable new capabilities for researchers at the Omaha VAMC and our affiliates at the University of Nebraska Medical Center (UNMC). Acquisition of the Spectramax will help us create new capabilities not currently available at this Medical Center. SpectraMax M Series will help to accelerate our research. Specifically, we are examining Veteran-relevant, preclinical disease models, including liver disease, diabetes and pulmonary disease in hopes of advancing the therapeutic interventions that will support the VA mission.